Biocept Stock News

Patented liquid biopsy technology called Target Selector detects cancer biomarkers Ramping up global marketing efforts for its blood tests and related products to grow organically Has received to da

Biocept Inc (NASDAQ:BIOC), the diagnostics-focused group, swung to a profit in its third quarter, recovering from the loss it reported in the corresponding period last year, thanks to a 165% increas

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update. With CNSide, our paradigm-changing neuro-oncology test that uses cerebrospinal fluid for diagnosing and monitoring patients with brain metastases, we are reporting strong sequential quarter volume growth, primarily driven by data generated with our acad

Biocept, Inc. (BIOC) CEO Michael Nall on Q3 2021 Results - Earnings Call Transcript

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

Biocept Inc (NASDAQ:BIOC) has announced the publication of a study showing that the addition of Switch-Blocker technology to common PCR-based liquid biopsy assays significantly increased sensitivity i

Battling cancer is often a long journey—and one that becomes even more challenging for the large number of patients who find that the cancer may have spread to their brain or spinal cord. Between 10

Biocept Inc has implemented its COVID-19 testing services at more than 30 community college campuses across California.  Also, the company said it is streamlining the testing and tracking process for

SAN DIEGO--(BUSINESS WIRE)--Biocept provides on-campus COVID-19 testing to over 30 California community colleges, as students and staff return to in-person learning.

These penny stocks are undervalued based on their fundamentals and have the potential to break through in the coming months. The post 7 of the Best Penny Stocks to Buy Coming Into Year-End appeared fi

SAN DIEGO--(BUSINESS WIRE)--Biocept presents data showing ultra-sensitive Switch-Blocker technology detects rare cancer mutations at RAS-Targeted Drug Development Summit.

SAN DIEGO--(BUSINESS WIRE)--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays and services, today announced that it has granted inducement stock options to purchase an aggregat

Biocept Inc (NASDAQ:BIOC) has announced new data from a study assessing its cerebrospinal fluid assay, CNSide. Data showed that CNSide detected tumor cells and identified actionable mutations in lung

Biocept Inc told investors that its cerebrospinal fluid assay CNSide had been shown to be able to detect markers of a complication of non-small cell lung cancer (NSCLC), which could mean targeted trea